Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis
Open Access
- 27 October 2025
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 32 (10) , e70382
Abstract
Background: Reliable biomarkers for amyotrophic lateral sclerosis (ALS) are urgently needed due to diagnostic and prognostic challenges. This systematic review and meta‐analysis aimed to synthesize recent evidence on the utility of blood and cerebrospinal fluid (CSF) biomarkers for ALS. Methods: We systematically reviewed studies published from January 1, 2019 to March 25, 2025, that evaluated blood or CSF biomarkers for ALS. Eligible studies reported diagnostic performance, group‐level biomarker values, hazard ratios (HRs) for survival, or correlations with functional rating scales or disease progression rates. Study quality was assessed using the QUADAS‐2 and QUIPS frameworks. Random‐effects models were employed to pool summary receiver operating characteristic (SROC) curves, HRs, standardized mean differences, and correlation coefficients. Results: We included 47 studies in the SROC analysis and 27 in the HR analysis, covering 9078 participants (5556 ALS and 3522 controls). Neurofilament light chain (NfL) consistently demonstrated the highest diagnostic accuracy (sensitivity/specificity: 0.81–0.87 vs. ALS mimics) and high prognostic value (pooled HRs: 2.8–4.3) in both blood and CSF. CSF chitinases and the p‐tau/t‐tau ratio showed moderate utility. Other biomarkers, including interleukins, had limited clinical relevance. Most studies showed moderate to high risk of bias, with methodological heterogeneity and limited transparency. Conclusions: NfL is the most validated biomarker for ALS diagnosis and prognosis, in both blood and CSF. However, its limited accuracy when used alone carries a considerable risk of misclassification. Future studies should adopt prevalence‐specific strategies and integrate biomarkers within multimodal frameworks to enhance diagnostic and prognostic precision.Keywords
Funding Information
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
This publication has 60 references indexed in Scilit:
- Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathiesJournal of the Peripheral Nervous System, 2018
- Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral SclerosisNeuropathology and Applied Neurobiology, 2018
- Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction modelThe Lancet Neurology, 2018
- Projected increase in amyotrophic lateral sclerosis from 2015 to 2040Nature Communications, 2016
- The phenotypic variability of amyotrophic lateral sclerosisNature Reviews Neurology, 2014
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Evaluation of the Quality of Prognosis Studies in Systematic ReviewsAnnals of Internal Medicine, 2006
- Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviewsJournal of Clinical Epidemiology, 2005
- El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2000
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982